&w=3840&q=100)
Anthem Biosciences lists at 27% premium; should you book profit or hold?
On the National Stock Exchange (NSE), Anthem Biosciences shares listed at a mildly lower premium of ₹153.05 or 26.85 per cent at ₹723.05 per share over the issue price.
Anthem Biosciences IPO listing came below the grey market estimate. Ahead of their debut on the bourses, the unlisted shares of Anthem Biosciences were exchanging hands at around ₹749 per share, reflecting a grey market premium (GMP) of ₹179 per share or nearly 31.40 per cent over the issue price of ₹570 per share, showed the sources that track unofficial market activities.
Should you book profit or hold?
The listing of the company's shares, Prashanth Tapse, senior VP (research), Mehta Equities, said was broadly in line with expectations. While post-listing valuations may appear premium, Tapse believes these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility.
"The ability to consistently deliver earnings growth, in line with street expectations, further supports its valuation," said Tapse, and recommended investors to 'hold' Anthem Biosciences for a long-term perspective.
"For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, justifying the listing. Short term, we foresee ₹900 as a target, while long-term investors can hold it for ₹1,000 and above. Non-allottees should wait for some volatility to settle in price, and in any case, if the stock is available around ₹650–680, it can be considered a good range to accumulate with a long-term vision," said Tapse.
Shivani Nyati, head of wealth at Swastika Investmart, on the other hand, recommended investors to secure partial profits. "The company is one of the leading global players in the CRDMO segment and enjoys a niche position, leading the pack of players. The company has shown steady growth in its top line during the reported periods," said Nyati.
She further recommended the investors to retain the remaining stake with a stop-loss set at ₹650.
Anthem Biosciences IPO details
Anthem Biosciences IPO comprised entirely an offer-for-sale (OFS) with promoters and shareholders divesting up to 59.6 million equity shares estimated to be worth ₹3,395 crore. The public issue was offered at a price band of ₹540–570 with a lot size of 26 shares, and was open for subscription from July 14, 2025, till July 16, 2025.
Anthem Biosciences received strong demand from investors for its public issue as it got oversubscribed by 63.86 times. The demand was led by the qualified institutional buyers (QIBs), who bid for 182.65 times the category reserved for them, showed the NSE data.
Anthem Biosciences, as outlined in its red herring prospectus (RHP), will not use any proceeds from the public issue, and it will be given to the promoters and shareholders selling their stakes through the OFS.
About Anthem Biosciences
Incorporated in 2006, Anthem Biosciences is a contract research, development, and manufacturing organisation (CRDMO) serving global customers. The company manufactures specialised fermentation-based APIs, including probiotics and enzymes. Anthem Biosciences has a diverse customer base, including biotech firms and large pharmaceutical companies, spanning over 44 countries. As of September 2024, the company had 196 projects and over 425 customers in its CRDMO business. The company holds one patent in India and seven overseas, with 24 pending global patent applications.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
20 minutes ago
- NDTV
PM Modi Lands In UK, Long-Awaited Free Trade Deal Expected Today: 10 Points
The free trade agreement is India's first major bilateral trade agreement with a developed economy in over a decade. A 10-point cheat sheet on the free trade agreement to be signed by India and the UK The free trade agreement between India and the UK will be signed during Prime Minister Narendra Modi's visit to London on July 24. Commerce and Industry Minister Piyush Goyal will accompany the prime minister. The two countries announced the conclusion of the negotiations for the trade agreement on May 6, after three years of negotiations. The trade agreement proposes to remove taxes on the export of labour-intensive products such as leather, footwear and clothing, while making imports of whisky and cars from Britain cheaper, in an effort to double trade between the two economies to USD 120 billion by 2030. After the free trade agreement is signed by the commerce ministers from both countries, it will require approval from the British Parliament before coming into effect, as the Indian cabinet has already given its consent to the deal. Britain is the sixth-largest investor in India with investments of around $36 billion. There are 1,000 Indian companies in the country, with 1,00,000 employees, with a total of $2 billion investment. 99% of Indian products will receive duty-free access to the UK market, covering nearly all of India's current trade value. Apart from the free trade agreement, the biggest the UK has done since leaving the European Union, the two sides also sealed a double contribution convention. It provides for exemption for employers of Indian workers from paying social security contributions in the UK. India's exports to the U.K. rose by 12.6% to $14.5 billion, while imports grew by 2.3% to $8.6 billion in 2024-25. The bilateral trade between India and the U.K. increased to $21.34 billion in 2023-24 from $20.36 billion in 2022-23. From London, PM Modi will travel to the Maldives at the invitation of President Mohamed Muizzu in what is being seen as a breakthrough in the ties between the two countries following a spell of frostiness under Mr Muizzu.
India Today
an hour ago
- India Today
PM Modi arrives in London for 2-day UK visit, trade deal key focus
Prime Minister Narendra Modi landed in London on Wednesday evening for a two-day official visit to the United Kingdom from July 23 to Prime Minister was received at the airport by UK Foreign Office Minister in charge of the Indo-Pacific Catherine West, along with Indian High Commissioner to the UK Vikram Dorsaiswami and British High Commissioner to New Delhi Lindy visit, described as 'historic' by Indian diaspora groups, marks the first leg of his two-nation tour and is expected to significantly boost bilateral ties between India and the arrival, PM Modi was welcomed by enthusiastic groups of community leaders, students, and parliamentarians gathered on the outskirts of London.'It's a great achievement for both the governments, and especially for the Indian diaspora, which is really excited to see the Prime Minister here after so many years. He's again here for a very short visit, but at least we get a chance to greet him,' said Kuldeep Shekhawat, President of the Overseas Friends of BJP (OFBJP) diaspora group to the news agency his visit, he is scheduled to hold wide-ranging discussions with British Prime Minister Keir Starmer and meet King Charles III. Starmer will host him at Chequers, the British prime minister's official country residence near centrepiece of the visit is expected to be the signing of a Free Trade Agreement (FTA) and a renewed push to enhance the India-UK Comprehensive Strategic Partnership (CSP).'Our collaboration spans a wide range of sectors, including trade, investment, technology, innovation, defence, education, research, sustainability, health and people-to-people ties,' said PM Modi in his departure Minister Piyush Goyal is likely to sign the free trade agreement alongside his UK counterpart Jonathan Reynolds and the two prime ministers, capping three years of hard bargaining. Britain sees the deal as its biggest trade win since Brexit and hopes it will inject fresh momentum into defence, research and tech partnerships with leaders are likely to focus on enhancing economic ties, with an emphasis on prosperity, growth, and job creation in both countries. PM Modi's visit underscores efforts to eliminate or reduce tariffs on imports and exports between the two nations under the proposed trade deal, which aims to make products from both countries more competitive. Both sides are targeting a bilateral trade volume of USD 120 billion by 2023–24, bilateral trade between the two countries crossed USD 55 billion. The UK is India's sixth-largest investor with USD 36 billion invested so far, while nearly 1,000 Indian companies in Britain employ around 1,00,000 people. Indian investments in the UK stand at close to USD 20 visit marks PM Modi's fourth to the United Kingdom since assuming office. He had previously visited in 2015, 2018, and in 2021 for the COP26 summit in Glasgow. Over the past year, Modi and Starmer have met twice—first at the G20 summit in Rio de Janeiro and more recently at the G7 summit in Kananaskis, Canada, in June.- EndsMust Watch IN THIS STORY#Narendra Modi
Mint
an hour ago
- Mint
Tilaknagar Industries acquires Imperial Blue whiskey for ₹4,150 crore
New Delhi: Homegrown liquor company Tilaknagar Industries Ltd on Wednesday announced the acquisition of Imperial Blue Brands from Pernod Ricard India Pvt. Ltd for an enterprise value of ₹ 4,150 crore, marking its foray into the country's whiskey segment. With the acquisition, the company will become one of the leading players in brandy and whiskey, the two largest Indian-made foreign liquor (IMFL) categories. Pernod Ricard said the sale strengthens its India portfolio, enabling the business to fully tap into premiumization trends and support sustained, profitable growth. As Pernod Ricard's second-largest market, India is a strategic priority, and this realignment improves the ability to capitalize on the country's strong macroeconomic fundamentals and long-term potential. Upon closing, the transaction is expected to be immediately and meaningfully accretive to Pernod Ricard India's operating margin and net sales growth rate, the company said. Mint had reported last September that Pernod Ricard had put Imperial Blue whiskey up for sale in India. In fiscal year 2023, India surpassed China as the second-largest market by net sales for the company, after the US. Pernod Ricard India sells mass-market brands such as Royal Stag, Blenders Pride and 100 Pipers, and premium ones such as Chivas Regal, Ballantine's, Glenlivet and Jameson Irish Whiskey. India's organized liquor industry recorded revenues of ₹ 4.45 trillion in FY24, according to a report by ratings firm Crisil. Pernod Ricard India posted a consolidated revenue from operations of ₹ 25,039 crore in FY23, up from ₹ 22,741 crore in FY22. In a filing to the exchanges on Wednesday, Tilaknagar Industries said its wholly-owned subsidiary Grain & Grape Works Pvt. Ltd (GGWPL) shall acquire the business undertaking of Pernod Ricard India Pvt. Ltd, as a going concern on a slump sale basis related to the business of production, bottling, marketing and sale of alcoholic and other beverages under the Imperial Blue brands for an enterprise value of ₹ 4,150 crores, including a deferred payment of ₹ 282 crores as on date. To finance this acquisition and support its future growth plans, Tilaknagar Industries has announced its plan to raise up to ₹ 6,500 crores, comprising up to ₹ 2,500 crores in equity and equity-linked securities and up to ₹ 4,000 crores via borrowing money or in debt securities from investors. This entire fundraising process will, of course, be subject to approval from the companies' shareholders and the relevant regulatory authorities. The transaction remains subject to the approval from the Competition Commission of India, and is expected to close within the coming months. Tilaknagar Industries, founded in 1933, is a major player in the IMFL industry, with a manufacturing footprint of 21 units across 12 states. Its brand portfolio includes brandy brand Mansion House and Courrier Napoleon, along with a strong presence in whisky, rum, and gin through Mansion House Whisky, Madiraa Rum, and Blue Lagoon Gin. Imperial Blue is currently the third largest brand in IMFL segment. Imperial Blue will boost Tilaknagar Industries' premium portfolio strategy. This acquisition would also strengthen its distribution network. The turnover of the business for the period April 2024 to March 2025 was ₹ 3,067 crores.
